2.565EUR-1.72%Mkt Cap: 469.00M EURP/E: —Last update: 2026-05-14
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese ence…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)5.67
PEG-13.06
P/B4.04
P/S3.00
EV/EBITDA-6.66
EV/Revenue3.49
EPS (TTM)-0.80
EPS (Forward)0.44
Cash Flow & Leverage
FCF Yield-6.61%
FCF Margin-19.83%
Operating CF-52.89M EUR
CapEx (TTM)4.48M EUR
Net Debt/EBITDA-1.27
Net Debt104.24M EUR
Technical
SMA 503.080 (-16.7%)
SMA 2003.862 (-33.6%)
Beta—
S&P 52W Chg24.23%
Avg Vol (30d)1.32M
Avg Vol (10d)1.82M
Technical Indicators
RSI (14)47.0
MACD-0.1272
MACD Signal-0.2089
MACD Hist.+0.0817
BB Upper2.757 EUR
BB Middle2.457 EUR
BB Lower2.157 EUR
BB Width24.41%
ATR (14)0.2152 EUR
Vol Ratio (20d)0.47x
52W Range
2.19012% of range5.415
52W High5.415 EUR
52W Low2.190 EUR
Profitability
Gross Margin38.66%
EBITDA Margin-52.38%
Profit Margin-65.95%
Oper. Margin-76.67%
ROE-108.50%
ROA-28.88%
Revenue Growth-37.20%
Earnings Growth—
Balance Sheet
Debt/Equity1.95
Current Ratio2.14
Quick Ratio1.23
Book Value/Sh0.6120 EUR
Cash/Share0.5910 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.189.65M
Float147.38M
Insiders10.72%
Institutions21.27%
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)5.283 EUR
Target Range2.100 EUR – 7.500 EUR
# Analysts6
Company
Market Cap469.00M EUR
Enterprise Value544.89M EUR
Revenue (TTM)156.33M EUR
Gross Profit67.52M EUR
Net Income (TTM)-115.19M EUR
Revenue/Share0.8970 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees674
Last Price2.565 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINCH0002088976